{
    "abstract": "To investigate the efficacy of the cephalosporin/ beta lactamase inhibitor combination ceftazidime-avibactam in hematology patients with hematopoietic stem cell transplantation or receiving chemotherapy alone.\nIn this study, 80 patients who were followed up in the Stem Cell Transplant Center and Hematology Clinic of Istinye University Gaziosmanpa\u015fa Medicalpark Hospital between June 2022 and May 2024 and who received ceftazidime-avibactam treatment for at least 3 days during their hospitalization were evaluated. Demographic characteristics, infectious processes, duration of hospitalization before culture, neutrophil levels and neutropenia duration at the time of treatment initiation, previous antibiotic exposure, Charlson's Comorbidity index, mechanical ventilation needs and mortality rates were recorded retrospectively.\nOf the patients, 25 (31.25%) were female and 55 (68.75%) were male. The mean age was 50 years (18-86). Thirty-four (42.5%) patients received allogeneic hematopoietic stem cell transplantation and 17 (21.25%) patients received autologous hematopoietic stem cell transplantation. Only 29 (36.25%) patients received chemotherapy. When ceftazidime-avibactam treatment was initiated, 42 (52.5%) patients had a neutrophil count\u2009<\u20090.1\u2009\u00d7\u200910\nMortality due to resistant microorganisms is high in hematologic patients during stem cell transplantation and non-transplant period. Age, pneumonia and need for mechanical ventilation and duration of neutropenia are the most important mortality indicators in hematologic patients. Ceftazidime-avibactam is an effective treatment option in appropriate patients and the clinical response will be better if it can be started before the need for mechanical ventilation develops.",
    "authors": [
        {
            "affiliation": "School of Medicine, Department of Hematology and Bone Marrow Transplantation Unit, Istinye University, Medicalpark Gaziosmanpasa Hospital, Istanbul, Turkey. aysunhalacoglu@hotmail.com.",
            "firstname": "Aysun",
            "initials": "A",
            "lastname": "Halacoglu"
        },
        {
            "affiliation": "School of Medicine, Department of Hematology and Bone Marrow Transplantation Unit, Istinye University, Medicalpark Gaziosmanpasa Hospital, Istanbul, Turkey.",
            "firstname": "Mustafa",
            "initials": "M",
            "lastname": "Koroglu"
        },
        {
            "affiliation": "School of Medicine, Department of Hematology and Bone Marrow Transplantation Unit, Istinye University, Medicalpark Gaziosmanpasa Hospital, Istanbul, Turkey.",
            "firstname": "Mehmet",
            "initials": "M",
            "lastname": "Ozen"
        }
    ],
    "conclusions": "Mortality due to resistant microorganisms is high in hematologic patients during stem cell transplantation and non-transplant period. Age, pneumonia and need for mechanical ventilation and duration of neutropenia are the most important mortality indicators in hematologic patients. Ceftazidime-avibactam is an effective treatment option in appropriate patients and the clinical response will be better if it can be started before the need for mechanical ventilation develops.",
    "copyrights": "\u00a9 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.",
    "doi": "10.1007/s10096-025-05107-7\n10.1016/j.ijantimicag.2015.05.003\n10.1002/phar.1622\n10.1016/S1473-3099(17)30753-3\n10.1093/cid/ciu052\n10.2147/IDR.S396428\n10.1038/s41375-022-01620-2\n10.1038/s41375-022-01613-1\n10.1016/S1473-3099(16)30004-4\n10.1016/0021-9681(87)90171-8\n10.3390/antibiotics11030321\n10.1007/s40121-023-00762-9\n10.1080/10428194.2016.1193859\n10.1016/j.ijantimicag.2021.106335\n10.1016/j.ijid.2017.03.021\n10.1093/jac/dkt002\n10.1097/MD.0000000000001931\n10.1080/14787210.2022.2020099\n10.2147/IDR.S419064\n10.4274/tjh.2014.0010",
    "journal": "European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology",
    "keywords": [
        "Ceftazidime-avibactam",
        "Hematopoietic",
        "Stem cell"
    ],
    "methods": null,
    "publication_date": "2025-03-18",
    "pubmed_id": "40097795\n26143591\n26289307\n29276051\n24463280\n36698726\n35732829\n35732831\n27107460\n3558716\n35326784\n36763243\n27339405\n33838223\n28392315\n23396855\n26559260\n34937518\n37546370\n26376622",
    "results": "Of the patients, 25 (31.25%) were female and 55 (68.75%) were male. The mean age was 50 years (18-86). Thirty-four (42.5%) patients received allogeneic hematopoietic stem cell transplantation and 17 (21.25%) patients received autologous hematopoietic stem cell transplantation. Only 29 (36.25%) patients received chemotherapy. When ceftazidime-avibactam treatment was initiated, 42 (52.5%) patients had a neutrophil count\u2009<\u20090.1\u2009\u00d7\u200910",
    "title": "Ceftazidime-avibactam use in hematology patients: single-center experience.",
    "xml": "<Element 'PubmedArticle' at 0x788505a5a5c0>"
}